Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Depreciation & Amortization: 2020-2025

Historic Accumulated Depreciation & Amortization for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $338,000.

  • Xeris Biopharma Holdings' Accumulated Depreciation & Amortization rose 10.10% to $338,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1.41%. This contributed to the annual value of $1.2 million for FY2024, which is 18.20% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Accumulated Depreciation & Amortization stood at $338,000, which was up 4.00% from $325,000 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Accumulated Depreciation & Amortization ranged from a high of $391,000 in Q3 2023 and a low of $281,000 during Q2 2024.
  • For the 3-year period, Xeris Biopharma Holdings' Accumulated Depreciation & Amortization averaged around $336,818, with its median value being $326,000 (2024).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 86.32% in 2021, then climbed by 15.66% in 2025.
  • Xeris Biopharma Holdings' Accumulated Depreciation & Amortization (Quarterly) stood at $349,000 in 2021, then rose by 5.16% to $367,000 in 2022, then fell by 2.18% to $359,000 in 2023, then fell by 12.81% to $313,000 in 2024, then increased by 10.10% to $338,000 in 2025.
  • Its last three reported values are $338,000 in Q3 2025, $325,000 for Q2 2025, and $315,000 during Q1 2025.